TYRA vs. ETNB, OPK, ARQT, IMNM, SAVA, TNGX, ZNTL, SPRY, ELVN, and SAGE
Should you be buying Tyra Biosciences stock or one of its competitors? The main competitors of Tyra Biosciences include 89bio (ETNB), OPKO Health (OPK), Arcutis Biotherapeutics (ARQT), Immunome (IMNM), Cassava Sciences (SAVA), Tango Therapeutics (TNGX), Zentalis Pharmaceuticals (ZNTL), ARS Pharmaceuticals (SPRY), Enliven Therapeutics (ELVN), and Sage Therapeutics (SAGE). These companies are all part of the "pharmaceutical preparations" industry.
Tyra Biosciences (NASDAQ:TYRA) and 89bio (NASDAQ:ETNB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings.
84.1% of Tyra Biosciences shares are held by institutional investors. 18.4% of Tyra Biosciences shares are held by company insiders. Comparatively, 4.4% of 89bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, 89bio had 8 more articles in the media than Tyra Biosciences. MarketBeat recorded 8 mentions for 89bio and 0 mentions for Tyra Biosciences. 89bio's average media sentiment score of 0.43 beat Tyra Biosciences' score of 0.00 indicating that 89bio is being referred to more favorably in the news media.
89bio received 80 more outperform votes than Tyra Biosciences when rated by MarketBeat users. Likewise, 62.09% of users gave 89bio an outperform vote while only 57.69% of users gave Tyra Biosciences an outperform vote.
Tyra Biosciences' return on equity of -30.26% beat 89bio's return on equity.
Tyra Biosciences is trading at a lower price-to-earnings ratio than 89bio, indicating that it is currently the more affordable of the two stocks.
Tyra Biosciences has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, 89bio has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500.
Tyra Biosciences currently has a consensus target price of $22.00, indicating a potential upside of 48.45%. 89bio has a consensus target price of $29.00, indicating a potential upside of 255.39%. Given 89bio's stronger consensus rating and higher probable upside, analysts plainly believe 89bio is more favorable than Tyra Biosciences.
Summary
89bio beats Tyra Biosciences on 9 of the 15 factors compared between the two stocks.
Get Tyra Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for TYRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TYRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tyra Biosciences Competitors List
Related Companies and Tools
